Besins Healthcare, a global lead in Women's and Men's Reproductive Health, today unveiled its novel hormone production facility in Muel, situated near Zaragoza, Spain. This event represents a significant moment in European pharmaceutical history.
Built in an astounding time frame since its foundation in mid-2022, this avant-garde facility adheres to the highest quality complying with the highest environmental standards. The plant fortifies Besins Healthcare's commitment to scale up production capacities within Europe, boosting their output by an impressive 30%.
Championing European Pharmaceutical Manufacturing
Following its strategic acquisition of a hormone production site in Drogenbos, Belgium, in 2022, Besins Healthcare continues to reinforce its commitment to the European Union's initiative to mitigate drug shortages and establish pharmaceutical sovereignty . "Being deeply rooted in Europe, it was a natural decision for us to invest here," said Nicolas & Alexandre Besins, CEOs, elaborating that the new facility will help "satisfy the surging global demand for hormone treatments related to menopause and fertility."
Meeting the Escalating Global Demand
The new facility is a timely response to an upsurge in demand for Hormonal Replacement Therapies (HRT). As demographics shift, an increasing number of women reach menopause, requiring female hormone (Estrogen and Progesterone) supplementation. In parallel, the average age for first-time pregnancies is climbing, leading to complex fertility scenarios that often necessitate Progesterone support.
Future-Ready Products and Collaborations
Dr. Pedro N. Barri, President of Dexeus Mujer, Barcelona, heralded the opening as "remarkable news in the therapeutic area," and particularly shared his anticipation: 'I look forward to manufacturing new dosages of natural Progesterone (300 and 400 mg)(2) to serve better our patients' needs'.
Comments powered by CComment